Welcome to our dedicated page for Nutriband SEC filings (Ticker: NTRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nutriband Inc. filings document material events for a Nevada public company developing prescription transdermal pharmaceutical products. Recent Form 8-K disclosures cover Regulation FD press releases related to the company’s abuse-deterrent fentanyl transdermal system and brand-name development, as well as board actions involving an operating subsidiary agreement.
The filing record also describes the company’s Nasdaq-listed common stock and warrants, annual meeting voting matters, director elections, auditor ratification, amendments to organizational documents, governance procedures, and other capital-structure and shareholder matters reported through current reports.
Nutriband Inc. filed a prospectus supplement updating its 424(b)(3) prospectus for public warrants covering up to 910,904 shares of common stock. The outstanding warrants stem from the company’s October 2021 unit offering and are immediately exercisable at an adjusted exercise price of $6.43 per share.
As of October 19–20, 2025, 910,904 warrants remained outstanding and trade on Nasdaq as NTRBW. On October 17, 2025, the last reported sale prices were $7.48 per share for common stock and $2.50 per warrant. Shares outstanding were 12,034,883 as of September 8, 2025; this is a baseline figure, not the amount being offered.
The supplement also incorporates the company’s latest Form 10-Q, which showed revenue of $622,452 for the quarter ended July 31, 2025 and cash and cash equivalents of $6,995,101 as of that date.